Aeon Biopharma, INC DEF 14A proxy statements

AEON Biopharma, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 17, 2026, detailing proposals for director elections and auditor ratification.

AEON Biopharma, Inc. is calling a Special Meeting of Stockholders on January 21, 2026, to approve a private placement, an exchange of convertible notes, and an amended equity incentive plan, all crucial for funding the development of ABP-450 as a biosimilar to BOTOX.

AEON Biopharma announced positive biosimilarity data for ABP-450, strategic financing, and extended cash runway into Q2 2026, alongside its Q3 2025 financial results.

AEON Biopharma announced up to $22 million in funding through a private placement and a debt-to-equity exchange with Daewoong, significantly strengthening its balance sheet and accelerating its ABP-450 biosimilar program.

AEON Biopharma, Inc. has filed a supplement to its proxy statement to correct an inadvertently stated quorum requirement for its upcoming 2025 Annual Meeting of Stockholders.

AEON Biopharma, Inc. is holding its 2025 Annual Meeting of Stockholders on June 13, 2025, to elect directors and ratify the appointment of its independent auditor.

AEON Biopharma is asking stockholders to approve an increase in authorized shares, a reverse stock split, and the issuance of warrants at a special meeting on February 24, 2025.

AEON Biopharma restates its 2023 financials due to an accounting error, leading to an amendment in its agreement with Daewoong and raising concerns about its ability to continue as a going concern.

AEON Biopharma is asking stockholders to approve a potential share issuance to Daewoong Pharmaceuticals, which could exceed 20% of outstanding stock and trigger a change of control provision.